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Complement phenotypes in glomerulonephritis: Increased frequency of
homozygous null C4 phenotypes in IgA nephropathy and Henoch-
Schönlein purpura. Polymorphism of three complement genes (C4A,
C4B, and BF) located within the major histocompatibility complex was
studied in 48 biopsy-proven IgA nephropathy patients and nineteen
patients with Henoch-Schonlein purpura (HSP). Polymorphism was
determined by immunoelectrophoretic techniques and functional activ-
ity using an overlay of sheep cells in agarose and C4 deficient sera. The
subjects were divided into four large groups according to the presence
or absence of a C4 null allele (a gene producing no identifiable gene
product): group 1 (no null variants), group 2 (one C4A null variant),
group 3 (one C4B null variant), and group 4 (two null variants at either
the C4A or C4B locus, that is, homozygous null). Patients had a
significantly increased frequency of group 4 phenotypes (homozygous
null); (12 of 67 patients, 17.8%) as compared to controls (4 of 102
patients, 3.9%, P = 0.0031). Both IgA (P = 0.045) and HSP patients (P
0.003) had a greater frequency of a C4 homozygous null phenotype.
The serum C4 concentration was higher in patients than in controls (740
mg/mi and 576 g/ml, respectively, P = < 0.001) whether evaluated
together or by C4 phenolypic group. The association between the
presence of IgA nephropathy or HSP with a homozygous C4 null
phenotype is of unknown significance but suggests a predisposition to
development of HSP or IgA nephropathy for individuals with the C4
homozygous null phenotype.
Phenotypes complementaires au cours des glomerulonephrites:
Fréquence augmentée de phenotypes C4 nul homozygotes lors de Ia
néphropathie a IgA et du purpura de Henoch-Schdnlein. Le
polymorphisme de trois genes du complement (C4A, C4B, et BF) situés
sur le complexe d'histocompatibilité principal a été étudié chez 48
malades atteints de néphropathie a IgA prouvée par Ia biopsie, et chez
dix-neuf malades atteints de purpura de Henoch-Schönlein (HSP). Le
polymorphisme a été déterminé par des techniques immuno-
electrophoretiques et l'activité fonctionnelle avec une couche de ccl-
lules de moutons sur agarose et des serums déficients en C4. Les sujets
ont été divisés en quatre grands groupes selon Ia presence ou l'absence
de l'allèle C4 nul (un gene ne produisant pas de substance génique
identifiable): groupe 1 (pas de variants nuls), groupe 2 (un variant C4A
nul), groupe 3 (un variant C4B nul), et groupe 4 (deux variants nuls sur
le locus C4A ou C4B, c'est, homozygote nul). Les malades avaient une
frequence significativement accrue de phenotypes du groupe 4
(homozygote nul) (12 du 67 malades, 17,8%) par rapport aux contrôles
(4 du 102 malades, 39%, P = 0,0031). Les malades IgA (P = 0,045) et
HSP (P = 0,003) avaient une plus grande frequence de phenotype C4
homozygote nul. La concentration sérique de C4 était plus éievée chez
les malades que chez les contrôles (740 mg/mI et 576 g/mg, respective-
ment, P = < 0,001), qu'ils soient évalués ensemble ou par groupe
phénotypique C4. L'association entre Ia presence d'une néphropathie a
IgA ou d'HSP avec un phenotype homozygote C4 nul a une signification
inconnue, mais suggère une predisposition au dèveioppement d'HSP ou
de néphropathie a IgA chez les individus porteurs du phenotype
homozygote C4 nul.
Polymorphism has been described for ten complement (C)
components [1—4]. The fourth component (C4) has been known
to be polymorphic [5], but the subsequent recognition of two
loci for C4 (C4A and C4B) within the major histocompatibility
complex was necessary before this polymorphism could be
adequately studied [6—8]. The C4 loci are equally polymorphic
as the adjacent HLA loci [9].
C4 genes which produce no detectable gene product (null C4
genes) occur at both C4 loci. An increased frequency of null C4
alleles has been reported in a few diseases [10, 11]. We report
an increased frequency of the presence of two null alleles at the
same C4 locus in patients with Henoch-Schonlein purpura
(HSP) and biopsy proven IgA nephropathy.
Methods
All patients and controls were Caucasian. Forty-eight pa-
tients with IgA nephropathy and 19 patients with HSP were
evaluated in Lexington, Kentucky. All patients with systemic
disease such as systemic lupus erythematosus, vasculitis,
chronic inflammatory disease of the liver, gastrointestinal tract,
or skin were excluded. The diagnosis of IgA nephropathy was
based on the demonstration by immunofluorescent microscopy
of IgA as the predominant immunoglobulin in a mesangial
distribution in the renal glomeruli. Some of these patients have
been previously described [12]. Extensive pedigree data were
available for all 48 IgA nephropathy patients. Eight of these
patients were found to share common ancestors [13], but the
closest relationship found for any individual was a great-great-
grandfather of one patient being the great-great-great grand-
father of another. No patient with HSP is known to be related
to another HSP or IgA nephropathy patient. The nineteen
patients with HSP all had evidence of renal involvement as
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manifested by proteinuria or hematuria on urinalysis. Renal
biopsy was performed in thirteen HSP patients. Henoch-
Schönlein purpura patients had the characteristic maculopap-
ular or petechial rash of this disease; most had other compo-
nents of the syndrome such as abdominal pain, arthralgia, and
general malaise.
The 102 individuals used as control subjects for both C4
phenotype and C4 concentration were unrelated native-born
Kentuckians having at least one parent born in Kentucky. No
control individual was known to be related to any HSP or IgA
nephropathy patient.
Serum creatinine concentration persistently greater than 1.4
mg/dl was the criterion for chronic renal insufficiency; endstage
renal failure was defined by the need for dialysis.
Complement phenotype and HLA analyses
Blood samples were collected in disodium ethylene-diamine
tetraacetate (EDTA), rapidly separated and preserved at
—70°C. Plasma was used for complement phenotype analysis
and either serum or plasma for the measurement of complement
protein concentrations.
Buffers for C4 phenotype analysis were prepared as previ-
ously described [61. All specimens were analyzed by im-
munofixation [7] and by crossed-gel immunoelectrophoresis [81.
When indicated, some specimens were also analyzed by a
functional overlay consisting of antibody labelled sheep cells in
agarose and hydrazine-treated guinea pig serum [7].
Factor B phenotype was determined by previously described
methods [14]. HLA typing was performed in the laboratory of
Dr. John S. Thompson (University of Kentucky, Lexington,
Kentucky) by standard techniques of the Southeastern Organ
Procurement Foundation [13]. The control population for HLA
allele frequencies was composed at 250 healthy Caucasian
blood donors from the central Kentucky Blood Center in
Lexington.
Serum concentration of C4
Serum C4 concentration was measured by radial immunodif-
fusion using monospecific antisera by previously described
methods [12]. The C4 concentration was usually determined at
the time of a routine office visit when the patient had no
intercurrent illness. If multiple C4 values were available, the
mean was reported.
Statistical analyses
The evaluation of differences in the frequency of complement
phenotypes and genotypes was performed by 2 analysis with
Yates' correction for small numbers where indicated. Means
and SDs were determined using computer programs. Relative
risk (RR) was calculated as homozygous null C4 positive cases
times homozygous null C4 negative controls divided by the
product of homozygous null C4 negative cases times C4
homozygous null positive controls. Complement component
nomenclature [15, 16] and C4 phenotype nomenclature follow
published recommendations [91.
C4 phenotypes have been divided into four groups: Group 1
includes all phenotypes which have no identifiable null variant
at either C4 locus. Random serum with a single null variant at
each C4 locus (hemizygous null phenotypes) cannot be dis-
tinguished from sera with no null alleles and would be included










39 (38.2) 30 (44.8) 0.7314 0.6029
Group 2
One C4A Null
26 (25.5) 11(16.4) 2.0443 0.1492
Group 3
One C4B Null
33 (32.4) 14 (20.9) 2.7273 0.0949
Group 4
Homozygous Null
4 (3.9) 12 (17.9)b 9.0306 0.0031
Total 102 67
a The x2 is performed as the 2 x 2 table with Yates' correction.
Seven patients with IgA nephropathy (14.6%) and live with HSP
(26.3%).
in this group. Group 2 includes patients with a single null at the
C4A locus. Group 3 includes patients with a single null pheno-
type at the C4B locus. All individuals with two null variants at
either the C4A or the C4B locus are in group 4 (homozygous
null).
Results
Frequency of C4 phenotypes in patients
The homozygous null phenotype (group 4) was significantly
increased in frequency for the combined IgA nephropathy and
HSP population (12 of 67 patients or 17.8%) compared with our
controls (Table 1). This increased frequency was found in both
IgA nephropathy (7 of 48 patients, 14.6% homozygous null, P
= 0.045) and in HSP (5 of 19 patients, 26.3% homozygous null,
P = 0.003). The frequencies of the other phenotypic groups
were not different from the controls. The presence of a
homozygous C4 phenotype was always confirmed by crossed-
gel immunoelectrophoresis (Fig. I). Of the eight patients shar-
ing a common ancestor with another patient, only one had a
homozygous C4 null phenotype.
Gene frequencies between controls and patients were not
significantly different from published studies [51. Three C4
phenotypes (C4A3,3 B1,1; C4A3,3 B1,Q0; and C4A3,Q0 B1,1)
account for 52% of our control group, 60% of one published
series [5], and 40.3% of our patients. Family studies in two
patients with IgA nephropathy confirmed the presence of one
null allele at each C4 locus (hemizygous null C4 phenotype).
One patient with HSP, who eventually required renal trans-
plantation, had three null C4 alleles (Fig. 2). The first two cases
were placed in group 1 and the third in group 4 because family
studies among controls were not performed.
The relative risk for the development of either IgA nephrop-
athy or HSP was increased if the individual carried the
homozygous C4 null phenotype (Table 2). The greatest risk was
for the development of HSP in carriers of C4A Q0,Q0 pheno-
type'(RR = 11.9); the smallest risk was for IgA nephropathy in
individuals with C4AQO,Q0 (RR = 2.1). Carriers of the
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null alleles by family studies), two had one null C4 allele and
one patient had no C4 null alleles. Among patients with IgA
nephropathy having endstage renal failure, none had a
homozygous C4 null phenotype.
Factor B and HLA phenotypes
No significant differences were detected between control and
patient gene frequencies for either factor B variants or HLA
antigens. An increased frequency of factor B Fast variant in
HSP (0.2500 versus 0.1700 in controls) was not statistically
different. Although the frequencies of HLA—Bw 35, Bw 44 and
DR4 and DR6Y—were higher in the patient population, the
increases were not significantly elevated when corrected for the
numbers of altigens. Six patients with the C4 homozygous null
phenotype hJ HLA analysis of family members; all patients
had different HLA haplotypes.
Discussion
Fig. 1. Crossed-gel immunoelectrophoresis for detection of C4 null
gene products (C4A*Q0 or C4B*Q0). A single null variant (C4A*QO)
is present in pane/i, indicated by the lower height of the acidic (right)
migrating protein. No null gene product can be seen in panel 2 since
peak heights are equal. A null allele at each C4 locus would also have
equal peaks (that is, hemizygous C4 null phenotype). A homozygous
null C4B specimen is shown in panel 3, indicated by the complete
absence of a peak in the basic area (left side) of this gel.
opment of either IgA nephropathy (RR 4.7) or HSP (RR
6.2).
C4 concentration
The concentration of serum C4 was higher in the patients
than in controls (740 216, 1 SD in patients and 576 164, 1
SD in controls; P < 0.001) (Fig. 3). The increased serum
concentration in patients occurred in all four phenotypic groups
but was significantly elevated in only two (groups 1 and 3).
Among patients, the mean C4 concentrations were lower in sera
with one or more null C4 alleles than in sera without null alleles,
yet the C4 concentration of patient sera was always higher than
the corresponding control group.
Clinical evaluation
The clinical characteristics of patients with HSP and IgA
nephropathy are similar to previous reports with respect to age
at onset and sex distribution (Table 3). The high incidence of
endstage renal failure in HSP (5 of 19 patients, 26.3%) and IgA
nephropathy (13 of 48 patients, 27.1%) may reflect selection
bias for patients with more serious disease. Among the HSP
patients who required dialysis or transplantation, two patients
had the homozygous null phenotype (one proven to have three
We report an increased frequency of the homozygous C4 null
phenotype at one or the other C4 locus in patients with
biopsy-proven IgA nephropathy and in HSP. This genetically
determined trait was found in 14.6% of biopsy-proven IgA
nephropathy patients and 26.3% of HSP patients. The signifi-
cantly increased frequency of homozygous null phenotype in
these two similar forms of glomerulonephritis may be a pre-
disposing factor for the development of the disease process,
although progression to renal failure in homozygous C4 null
patients was notable only among HSP patients.
The relationship between the homozygous C4 null phenotype
and the development of glomerulonephritis is speculative.
Three general mechanisms of disease may be considered. First,
the occurrence of IgA nephropathy or HSP may be due to
specific biological consequence of the homozygous C4 null
phenotype. The possibility that reduced serum C4 concentra-
tion (due to two null alleles) might participate in the etiology of
these diseases is not supported by our data since patients have
a higher mean C4 concentration than controls. When patient
specimens are analyzed according to the C4 phenotype, the
elevated mean C4 concentration in the patient group can be
attributed largely to C4 phenotype groups 1 and 3. Differing
biological activity of certain complement alleles might also
explain the association between complement alleles and dis-
ease. For example, the C4*A6 allele (when linked with HLA
B17) is a nonfunctioning C4 variant; yet the same C4A allele is
fully functional when linked to HLA-B37 [17]. The C4B alleles
have greater hemolytic activity, particularly following pre-
treatment with neuraminidase. In one study, a comparison of
biological activities among C4 phenotypes did not demonstrate
consistent differences in the specific C4 hemolytic activity
where analyzed by a number of C4 genes [18]. It is important to
note that while there is an increased frequency of homozygous
C4 null phenotype (group 4), this situation is not accompanied
by an increased frequency of C4 null genes in the patients.
While our results suggest that the presence of the homozygous
null phenotype increases risk to the development of IgA
nephropathy and HSP, this possible predisposition cannot be
attributed presently to either differences in C4 concentration or
C4 function between various C4 phenotypes.
A second explanation for the association of homozygous C4
phenotypes with IgA and HSP nephropathy could be as a
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A) A2, Bw44, DR3, MT2, BFS, C4AQO. C4BQO
C) A2, B40, DR4, MT2, BFS, C4A3, C4B2
1C4 = 740 gg/ml)
A) A2, Bw44, DR3, MT2, BFS, C4AQO, C4BQO
D) A24, B35, DR1, MT1, BFS, C4A3, C4BQO
(C4 = 500 p.g/mI)
Shaded area = C4 Null allele
Normal C4 = 580 160 (so) ,.g/mI
Fig. 2. Pedigree of patient 63 (HSP) showing HLA and complement phenotype. The plasma C4 concentration is shown in parentheses. The
haplotype of the father (A) had a null C4 gene at both the C4A and C4B loci and the maternal haplotype (D) contributed a third C4B null allele.
Despite three null C4 alleles, the plasma C4 concentration of the patient (arrow) was normal.
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consequence of the known linkage of C4 with histocompatibility
and immune response genes or to a linked disease associated
gene. Unlike previous reports [19—26], we found no significant
evidence of association of a particular HLA antigen with IgA
nephropathy in our patient population. Furthermore, the six
patients with homozygous C4 null phenotypes who had family
studies had different HLA haplotypes. Our patients provided no
evidence that any "extended haplotype" such as HLA Al, B8,
DR3, C4AQO, C4BI, C2', BFS [271 was associated with HSP or
IgA nephropathies. We conclude that the possible participation
of HLA antigens (as sites of uptake of cross-reacting infectious
agents or as altered HLA antigens which induce autoimmune
disease [281) in the pathogenesis of IgA nephropathy or HSP is
not supported by our data. The possibility that our study
population was in-bred is unlikely to explain our findings, since
patients known to be distantly related have a similar frequency
of null C4 phenotype as the entire patient population, and the
increased frequency of homozygous C4 null phenotype is not
accompanied by an increased gene frequency for either C4A or
C4B null genes in patients.
Fig. 3. The concentration of C4 for the controls (open bar) and the
patients (dark bar) according to the C4 phenotype. The C4 concentra-
tion is highest in sera with no identifiable C4 null alleles (group 1) and
was significantly higher than in patients from groups I and 3 (one C4
null). There was no significant difference between controls and patients
in groups 2 (one C4A null) and 4 (homozygous C4 null).
Finally, the association between C4 null phenotype and these
diseases may be coincidental. However, reports of genetic
complement deficiencies and disease suggests that our findings
are more than chance. Familial total deficiency of C2 has been
detected in patients with membranous glomerulonephritis [291,
membranoproliferative glomerulonephritis [301, and HSP [31,
321. If family members are evaluated, it is apparent that partial
complement deficiencies are also present in some patients with
glomerulonephritis [33—361. The determination of C4 pheno-
types in juvenile onset diabetes mellitus showed an increased
frequency for homozygous null C4 phenotypes flOj and the
homozygous null C4A phenotype is particularly increased in
systemic lupus erythematosus 1111. A rare C4B variant
V/Al
VAl
A) A2, Bw44, DR3, MT2, BFS, C4AQO, C4800
[Derivedi
C) A2, B40, DR4, MT2, BFS, C4A3, C4B2
D) A24, B35, DR1, MT1, BFS, C4A3, C4BQO
(C4 = 700 p.g/mI)
I) II/
Table 2. Relative risk for IgA nephropathy or HSP in individuals with
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Range 3 to 56 3 to 71
Number cases 48 19
Sex (MIF) 35/13 14/5
Creatinine, mg/dl
Initial 1.9 1.9
Range 0.5 to 10.8 0.4 to 6.2
Recent 1.1 0.8
Range 0.4 to 3.3 0.5 to 1.9
Outcome (No. patients) (48) (9)
Creatinine <1.4 mgldl 31 8
Creatinine >1.4 mg/dI 4 0
Dialysis 9 2
Transplant 4 3
(C4B*2.9) has been reportred to occur more frequently in
patients with glomerulonephritis than controls (25% vs. 2%),
but the patient number for each diagnostic group was quite
small [37]. The inheritance of four C4 null genes results in total
congenital C4 deficiency; patients with this condition com-
monly have a systemic lupus erythematosus-like illness [38—42],
repeated infections [40], glomerulonephritis [41], or HSP [42].
Total deficiencies of specific complement components are
clearly associated with disease, yet the mechanism(s) of these
associations remain(s) incompletely understood.
Acknowledgments
This investigation was supported by grants AM25216, AM3 1920, and
RRO5 374 from the National Institutes of Health and in part by awards
(Project 124 and 132) from the Lexington branch, Dialysis Clinics
Incorporated, Nashville, Tennessee. Dr. R. H. McLean was also
supported in part by the Gallagher Fund and the Hospitals for
Consumptives of Maryland (Eudowood), Baltimore, Maryland. Dr. R.
J. Wyatt is the recipient of Clinical Investigator Award AM00777 from
the National Institute of Arthritis, Kidney, Diabetes and Digestive
Diseases. Technical assistance was provided by D. Halatek, M. Mer-
row, and C. Schaefer. The authors thank R. Dugué for secretarial help.
Reprint requests to Dr. R. H. McLean, Division of Nephrology,
Department of Pediatrics, Johns Hopkins School of Medicine, Brady
301, 600 N. Wolfe Street, Baltimore, Mary/and 21205, USA
References
1. LACHMANN PJ, HOBART JJ: The genetics of the complement
system. Ciba Found Symp 23 1—250, 1979
2. HAUPTMANN G: Genetic polymorphism of human complement
proteins. Rev Fr Transfus Immunohematol 22:587—614, 1979
3. RODRIGUEZ DE CORDOBA S, FERREIRA A, NUSSENZWEIG V,
RuBIN5TEIN P: Genetic polymorphism of human C4—binding pro-
tein. J Immunol 131:1565—1569, 1983
4. RODRIGUEZ DE CORDOBA S, RUBENSTEIN P: Genetic polymorph-
ism of human factor H (B H). J Immunol 132:1906—1908, 1984
5. ROSENFIELD SI, RUDDY S, AUSTEN KF: Structural polymorphism
of the fourth component of human complement. J C/in Invest
48:2283—2292, 1969
6. O'NEILL GJ, YANG SY, DUPONT B: Two HLA-linked loci control-
ling the fourth component of human complement. Proc Nat Acad
Sd USA 75:5165—5 169, 1978
7. AWDEH ZL, ALPER CA: Inherited structural polymorphism of the
fourth component of human complement. Proc Nat Acad Sci USA
77:3576—3580, 1980
8. AWDEH AL, RAUM D, ALPER CA: Genetic polymorphism of
human complement C4 and detection of heterozygotes. Nature
282:205—206, 1979
9. MAUFF G, ALPER CA, AwDEH Z, BATCHELOR JR, BERTRAMS J,
BRUUN—PETERSEN G, DAwKINS RL, DEMANT P, EDWARDS J,
GROSSE—WILDE H, HAUPTMANN G, KLOUDA P, LAMM L, M0L-
LENHAUER E, NERL C, OLAISEN B, O'NEILL G, RITTNER C, Roos
MH, SKANES V, TEISBERG P, WELLS L: Statement on the nomen-
clature of human C4 allotypes. Immunobiology 164:184-191, 1983
10. RAUM D, AWDEH Z, ALPER CA: BF types and the mode of
inheritance of insulin-dependent diabetes mellitus (IDDM). Im-
munogenetics 12:59—74, 1981
11. FIELDER AHL, WALPORT MJ, BATCHELOR JR, RYNES RI, BLACK
CM, Doni IA, HUGHES RV: Family study of the major histo-
compatibility complex in patients with systemic lupus
erythematosus: Importance of null alleles of C4A and C4B in
determining disease susceptibility. Br Med J 286:425—428, 1983
12. JULIAN BA, WYATT RJ, MCMORROW RG, GALLA JH: Serum
complement proteins in IgA nephropathy. C/in Nephrol
20:251—258, 1983
13. JULIAN BA, WYATT RJ, QUIGGINS PA, WOODFORD S, GLEASON
K, THOMPSON JS: Evidence that IgA nephropathy is an inherited
disease (abstract). C/in Res 32:450A, 1984
14. MCLEAN RH, KENNEDY TL, BALLOW M, GAuDI0 KM, SIEGEL
NJ: Increased frequency of factor B Fast variant (BF*F) in the
idiopathic nephrotic syndrome. Disease Markers 1:25—32, 1983
15. NOMENCLATURE OF COMPLEMENT. Bull WHO 39:935—938, 1968
16. NOMENCLATURE OF THE ALTERNATIVE ACTIVATING PATHWAY OF
COMPLEMENT. J Immuno/ 127:1261—1262, 1981
17. O'NEILL GJ, NERL C, POLLACK MS: Analysis of active and
inactive complement C4 complotypes associated with subtypes
HLA—Bl7 in different racial groups. Am J Hum Genet 35:309—3 17,
1983
18. MAUFF G, BENDER K, GILES CM, GOLDMANN S, OPFERKUCH W,
WACHAUF B: Human C4 polymorphism: Pedigree analysis of
qualitative, quantitative, and functional parameters as a basis for
phenotype interpretations. Hum Genet 65:362—372, 1984
19. SABATIER JC, GENIN C, ASSENAT H, COLON S, DUCRET F,
BERTHOUX FC: Mesangial IgA glomerulonephritis in
HLA-identical brothers. C/in Nephrol 11:35—38, 1978
20. TOLKOFF—RUBIN NE, C0sIMI B, FULLER T, RUBIN RH, COLvIN
RB: IgA nephropathy in HLA-identical siblings. Transp/antation
26:430—433, 1978
21. BERTHOUX FC, GAGNE A, SABATIER JC, DUCRET F, LEPETIT JC,
MARCELLIN M, MERCIER B, BRIGARD CP: HLA—Bw35 and mesan-
gial IgA glomerulonephritis. N Eng/ J Med 298: 1034-1035, 1978
22. RICHMAN AV, MAHONEY JJ, FULLER TJ: Higher prevalence of
HLA—Bl2 in patients with IgA nephropathy (abstract). Ann Intern
Med 90:201, 1979
23. K0M0RI K, NOSE Y, INOUYE H, TSUJI K, NOMOTO Y, SAKAI H:
Study on HLA system in IgA nephropathy. Tissue Antigens
14:32—36, 1979
24. SENGER DPS, RASHID A, COUTURE RA, SCHIEMAN C, ACHARYA
C, WOLFISH NM: HLA and familial benign hematuria: Trans-
plantation 31:310—311, 1981
25. KATZ A, CARANICOLAS 5, FALK JA: Family study in IgA nephritis.
The possible role of HLA antigens. Transp/antation 29:505—506,
1980
26. NOEL LH, DESCI-IAMPS B, JUNGERS P, BACH JF, BUSSON M, SUET
C, HORS J, DAUSSET J: HLA antigen and three types of glomerulo-
nephritis. C/in Immuno/ Immunopathol 10:19—23, 1978
27. AWDEH ZL, RAUM D, YUNIS EJ, ALPER CA: Extended
HLA/complement allele haplotypes: Evidence for T/t—like complex
in man. Proc Nat Acad Sci USA 80:259—263, 1983
28. FARID NR: HLA in Endocrine and Metabolic Disorders. New
York, Academic Press, 1981, p 332
29. PICKERING Ri, MICHAEL AF, HERDMAN RC, GooD RA, GEWURZ
H: The complement system in chronic glomerulonephritis. Three
newly associated aberrations. J Pediatr 78:30—43, 1971
30. KIM Y, FRIEND PS, DRESNER IG, YUNI5 EJ, MICHAEL AF:
860 McLean et al
Inherited deficiency of the second component of complement (C2)
with membranoproliferative glomerulonephritis. Am J Med
62:765—771, 1977
31. SUSSMAN M, JONES JH, ALMEIDA JD, LACHMAN PJ: Deficiency of
the second component of complement associated with ana-
phylactoid purpura and presence of mycoplasma in the serum. C/in
Exp Immunol 14:53 1—539, 1973
32. GELFAND EW, CLARKSON JE, MINTA JO: Selective deficiency of
the second component of complement in a patient with
anaphylactoid purpura. C/in Immunol Immunopathol 4:269—276,
1975
33. RUSSELL BA, BOURKE E, NAYEF M, MORRIS S, PETERS DK:
Complement deficiency and nephritis. A report of a family. Lancet
1:675—677, 1980
34. WYATT RJ, JULIAN BA, WEINSTEIN A, ROTHFIELD NF, MCLEAN
RH: Partial H (Beta IH) deficiency and glomerulonephritis. J Clin
Immunol 2:110—1 17, 1982
35. MCLEAN RH, WEINSTEIN A, DAMJANOV T, ROTFIFIELD N:
Hypomorphic variant of C3, arthritis and chronic glomerulonephri-
tis. J Pediatr 93:937—943, 1978
36. COLEMAN TH, FORRISTAL J, KOSAKA T, WEST CD: Inherited
complement component deficiencies in membranoproliferative gb-
merulonephritis. Kidney mt 24:681—690, 1983
37. WANK R, O'NEILL GJ, HELD E, SCHENDEL DJ, RIETHMULLER G,
FEUCHT HE: Rare variant of complement C4 is seen in high
frequency in patients with primary glomerulonephritis. Lancet
1:872—874, 1983
38. BALLOW M, MCLEAN RH, YuNls EJ, AWDEH ZL, O'NEILL GJ,
EINARSON M, ALPER CA: C4 polymorphism and HLA linkage:
Studies in a family with hereditary C4 deficiency. C/in Immunol
Immunopathol 20:354—360, 1981
39. KJELLMAN M, LAURELL A—B, LAW B, SJOHOLM AG: Homozy-
gous deficiency of C4 in a child with a lupus erythematosus
syndrome. C/in Genet 22:33 1—339, 1982
40. MASCART—LEMONE F, HAUPTMANN G, GOETZ J, DUCHATEAU J,
DELESPESSE G, VRAY B, DAB I: Genetic deficiency of C4 presenting
with recurrent infections and SLE-like disease. Am J Med
75:295—304, 1983
41. SCHALLER JG, GILLILAND BG, OCHS HD, LEDDY JP, AG000S
LCY, ROSENFELD SI: Severe systemic lupus erythematosus with
nephritis in a boy with deficiency of the fourth component of
complement. Arthritis Rheum 20:1519—1525, 1977
42. TAPPEINER G, SCHOLZ S, LINERT J, ALBERT E, WOLFF K:
Hereditary deficiency of the fourth component of complement:
Study of a family. INSERM 80:399—404, 1978
